Multimodality treatment of esophageal cancer: a review of the current status and future directions.

Current Oncology Reports
Thomas NgHoward Safran

Abstract

Surgical resection will cure only 15% to 20% of patients with seemingly localized esophageal cancer. Multimodality therapy has the potential to increase the cure rate by improving locoregional control and preventing systemic relapse. Randomized trials demonstrate that chemoradiation followed by surgery decreases local relapse as compared with surgery alone; however, the effect on overall survival remains uncertain. The additional impact of surgery following chemoradiation also remains unclear, with two randomized trials demonstrating an improvement in locoregional control without a benefit in survival. Morbidity and mortality of trimodality therapy have limited potential gains. Incorporation of docetaxel, irinotecan, and oxaliplatin into chemotherapy regimens prior to chemoradiation or as adjuvant therapy may decrease systemic recurrence. New radiation sensitizers may improve locoregional control. Biologic agents, such as cetuximab, trastuzumab, erlotinib, and bevacizumab, may enhance chemoradiation and target systemic micrometastases. Advances in radiation oncology and surgery may decrease morbidity and mortality from trimodality therapy, improving patient outcome.

References

Mar 1, 1990·The Annals of Thoracic Surgery·M B OrringerJ Bromberg
Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A ForastiereM Zahurak
Jul 20, 1994·Journal of the National Cancer Institute·J A AjaniD P Kelsen
Jun 1, 1993·Cancer·H ChoyD D Von Hoff
Aug 15, 1996·The New England Journal of Medicine·T N WalshT P Hennessy
Feb 1, 1997·Endocrine Reviews·N Ferrara, T Davis-Smyth
Dec 31, 1997·The Journal of Thoracic and Cardiovascular Surgery·C D WrightD J Mathisen
Dec 31, 1998·The New England Journal of Medicine·D P KelsenJ A Roth
Apr 21, 1999·Current Opinion in Cell Biology·P O HackelA Ullrich
Sep 24, 1999·Annals of Surgery·M B OrringerM D Iannettoni
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E I HeathA A Forastiere
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J AdelsteinG Zuccaro
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S G UrbaM Strawderman
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Apr 9, 2001·Cancer Investigation·H SafranH J Wanebo
Jul 24, 2001·The Annals of Thoracic Surgery·J B HulscherJ J van Lanschot
Nov 3, 2001·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C M NuttingS Webb
Jun 7, 2002·Lancet·UNKNOWN Medical Research Council Oesophageal Cancer Working Group
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nikhil I KhushalaniLawrence Leichman
Aug 10, 2002·Annals of Surgery·Nasser AltorkiJeffrey Port
Oct 3, 2002·Nature Reviews. Cancer·Robert Kerbel, Judah Folkman
Nov 22, 2002·The New England Journal of Medicine·Jan B F HulscherJ Jan B van Lanschot
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H IlsonBruce D Minsky
Aug 12, 2003·International Journal of Radiation Oncology, Biology, Physics·Stephen G SwisherJack A Roth
Oct 8, 2003·Annals of Surgery·James D LuketichHiran C Fernando
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Baruch BrennerDavid P Kelsen
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael StahlHansjochen Wilke
Aug 3, 2005·American Journal of Clinical Oncology·James Y TsaiHoward Safran
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Nov 22, 2005·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Anurag ChandraRitsuko Komaki

❮ Previous
Next ❯

Citations

Dec 23, 2006·Seminars in Radiation Oncology·Mohan Suntharalingam
May 28, 2011·The British Journal of Surgery·S F SchoppmannP Birner
Nov 23, 2010·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·S-M CheL Hou
Nov 22, 2011·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Y WangJ Qin
Nov 6, 2007·International Journal of Radiation Oncology, Biology, Physics·Howard SafranTeresa Kennedy
Nov 26, 2010·The American Journal of Surgical Pathology·Sebastian F SchoppmannPeter Birner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Christopher G Willett
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Zhongxing LiaoRitsuko Komaki
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S G UrbaM Strawderman
Seminars in Oncology
Baruch BrennerBruce D Minsky
© 2022 Meta ULC. All rights reserved